We are live on ! Find out more
SMV

Sofinnova Management VIII Portfolio holdings

AUM $183M
1-Year Est. Return 4.18%
This Fund
S&P 500
This Quarter Est. Return
+8.48%
1 Year Est. Return
+4.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$190M
AUM Growth
+$11.9M
Cap. Flow
+$196K
Cap. Flow %
0.1%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
1
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$46.1M
2
CYTO
Altamira Therapeutics Ltd
CYTO
+$2.01M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$21.6M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$14M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$842M
$45.9M 24.21%
1,539,480
-750,000
-33% -$21.6M
OBSV
2
DELISTED
ObsEva SA Ordinary Shares
OBSV
$39M 20.59%
+3,749,623
New +$46.1M
ONCE
3
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$37.3M 19.68%
699,430
-205,556
-23% -$12.2M
ARAV
4
DELISTED
Aravive, Inc. Common Stock
ARAV
$33.4M 17.6%
260,543
-133,120
-34% -$14M
NTRA icon
5
Natera
NTRA
$44.8B
$13.8M 7.25%
1,550,280
– –
CYTO
6
DELISTED
Altamira Therapeutics Ltd
CYTO
$7.19M 3.79%
98
+25
+34% +$2.01M
SYBX
7
DELISTED
Synlogic
SYBX
$6.51M 3.44%
28,332
– –
OCGN icon
8
Ocugen
OCGN
$451M
$3.59M 1.9%
34,617
– –
INNL
9
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$2.36M 1.24%
2,103,173
– –
SPHS
10
DELISTED
Sophiris Bio, Inc.
SPHS
$566K 0.3%
200,000
– –

Similar funds

BIC
Bridges Investment Counsel Omaha, Nebraska $181M AUM 21.67% 1-Year Est. Return
CCM
CrestPoint Capital Management Four Seasons, Missouri $180M AUM 21.37% 1-Year Est. Return
YP
Yellowstone Partners Idaho Falls, Idaho $177M AUM
EI
Elkhorn Investments Chicago, Illinois $191M AUM 17.81% 1-Year Est. Return
W
WealthShield Cary, North Carolina $164M AUM
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
WI
Welch Investments Birmingham, Alabama $157M AUM 17.66% 1-Year Est. Return
TCM
Texan Capital Management Houston, Texas $154M AUM 98.25% 1-Year Est. Return

Sofinnova Management VIII's Q1 2017 Portfolio in Review

As of Q1 2017, Sofinnova Management VIII held 10 positions worth $190M, up 6.7% from $178M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sofinnova Management VIII's Q1 2017 filing shows 1 new, 1 increased and 3 reduced positions. Its largest new stake was ObsEva SA Ordinary Shares: 3,749,623 shares worth $39M. The largest sale was Aclaris Therapeutics, an estimated $21.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sofinnova Management VIII's largest Q1 2017 buy was ObsEva SA Ordinary Shares: 3,749,623 shares worth $39M.
  • Sofinnova Management VIII added most to Altamira Therapeutics Ltd in Q1 2017, an estimated $2.01M increase.
  • Sofinnova Management VIII's biggest Q1 2017 reduction was Aclaris Therapeutics, cutting an estimated $21.6M.
  • Sofinnova Management VIII's ten largest holdings make up 100% of its $190M portfolio in Q1 2017.
  • Sofinnova Management VIII opened 1 new position and closed 0 in Q1 2017.
  • Sofinnova Management VIII's portfolio value rose 6.7% quarter-over-quarter to $190M.

Based on Sofinnova Management VIII's 13F filing for Q1 2017, filed 10 Apr 2017.